PharmaEssentia (TPE:6446) secured approval from China's National Medical Products Administration to proceed with the phase three clinical trial of its drug Ropeginterferon alfa-2b (P1101).
The drug is indicated for patients with pre-fibrotic/early primary myelofibrosis (PMF) or overt PMF at low or intermediate-1 risk, according to a Taiwan Exchange filing.
The trial will assess the efficacy and safety of the drug, which is already approved for Polycythemia Vera (PV) in over 40 countries.
The pharmaceutical company expects patient recruitment to be completed in 2025, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.